Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis

N J McHugh; M Csuka; H Watson; G Belcher; A Amadi; E F Ring; C M Black; P J Maddison

Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis

N J McHugh, M Csuka, H Watson, G Belcher, A Amadi, E F Ring, C M Black, P J Maddison

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.

Original language	English
Pages (from-to)	43-47
Number of pages	5
Journal	Annals of the Rheumatic Diseases
Volume	47
Issue number	1
Publication status	Published - 1988

Keywords

Clinical Trials as Topic
Double-Blind Method
Epoprostenol
Female
Humans
Iloprost
Injections, Intravenous
Male
Raynaud Disease
Scleroderma, Systemic

Cite this

@article{c4dd6137e90b406fa82f3897e150a1b8,

title = "Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis",

abstract = "Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.",

keywords = "Clinical Trials as Topic, Double-Blind Method, Epoprostenol, Female, Humans, Iloprost, Injections, Intravenous, Male, Raynaud Disease, Scleroderma, Systemic",

author = "McHugh, {N J} and M Csuka and H Watson and G Belcher and A Amadi and Ring, {E F} and Black, {C M} and Maddison, {P J}",

year = "1988",

language = "English",

volume = "47",

pages = "43--47",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group Ltd",

number = "1",

}

TY - JOUR

T1 - Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis

AU - McHugh, N J

AU - Csuka, M

AU - Watson, H

AU - Belcher, G

AU - Amadi, A

AU - Ring, E F

AU - Black, C M

AU - Maddison, P J

PY - 1988

Y1 - 1988

N2 - Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.

AB - Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.

KW - Clinical Trials as Topic

KW - Double-Blind Method

KW - Epoprostenol

KW - Female

KW - Humans

KW - Iloprost

KW - Injections, Intravenous

KW - Male

KW - Raynaud Disease

KW - Scleroderma, Systemic

UR - http://ard.bmj.com/

M3 - Article

C2 - 2449871

SN - 0003-4967

VL - 47

SP - 43

EP - 47

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -

Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis

Abstract

Keywords

Other files and links

Fingerprint

Cite this